Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: ending an erratic month

November 30, 2018 7:17pm

Out and about: Shares of Fate Therapeutics (FATE) were up 8.94 (+$1.26 to $15.36)% as the U.S. FDA accepted its IND application for FT500, a potential natural killer cell cancer immunotherapy for advanced tumors. Shares of FATE had a 52 week change of +221.18% in the year to date. While Editas Medicine (EDIT) closed up +3.49% (+$1.05 to $31.16 as U.S. FDA accepted its IND application for EDIT-101, an experimental CRISPR genome editing medicine being investigated for the treatment of Leber Congenital Amaurosis type 10 (LCA10). Year to date, EDIT had a 52 week change of +0.60%

Pre-open indications: CRISPR Therapeutics (CRSP) closed down -$0.39 – miss; investors are afraid of the possibilities of their research.

There is no breadline for share pricing and fact based intelligence!

Some have stated, “I am the “weatherman” of the sector; forecasting and presenting conditions of the sector in a given period.”

The end-of-the-month take-away, don’t dwell on what’s happened and follow RMi’s lesson of investing in those who guide and then meet short-term expectation

Daily analytics and metrics:

The Dow closed UP +199.62 or +0.79% to 25,538.46
The S&P closed UP +22.22 points or +0.81% to 2,759.98
The NASDAQ was UP +57.45 points or +0.79% to 7,330.54

From the pre-open newsletter: “the invisible news, no good or even bad news. Cause and effect: finding sustainable value in “our” universe is lacking. Are risk fears and concerns any better than we were in relation to October and the coming of December?”

The advance/decline line scenario of 45 covered companies:

The open was negative with an A/DL of 21/22 and 2 flat;
The close was positive with an A/DL of 22/18 and 5 flat;

Pre-open indications:

CRISPR Therapeutics (CRSP) closed down -$0.39 – miss;

Daily sector metrics:

… Greatest volume to the downside: HSGX, GBT, BMRN, ONVO and ADRO

… Upside volume was weighted to: FATE, SGMO, XON, BLCM and MDXG

… Weakness ($) to the downside: CRSP (-$0.39), CLLS (-$0.25), RARE (-$0.24), VYGR (-^0.13) and OSIR (-$0.05)

… Best moves ($) to the upside … FATE (+$1.26), SAGE (+$1.25), EDIT (+$1.050, AXGN (+$1.02) and RENE.L (+$1.00)

The iShares NASDAQ Biotechnology (IBB) closed:

Friday was UP +1.50% after NOT indicating in the pre-market;
Thursday was down -0.05% after NOT indicating in the pre-market;
Wednesday was up +2.71% after indicating a POSITIVE +0.66% in the pre-market;
Tuesday was down -0.3% after NOT indicating in the pre-market;
Monday was up +1.7% after NOT indicating in the pre-market;
Last Friday was up +0.40% after NOT indicating in the pre-market;

Henry’omics:

Sector equities closed a volatile month with a gain on Friday as traders wobbled on trading values.

GLAD its OVER ...

Heading into December, however, sector equities could be in for more volatility – more than November, October and September?

Leading the upside were FATE (+$1.26), SAGE (+$1.25) and EDIT (+$1.05) while the losers were RGNX (-$2.52), BLUE (-$2.25), BMRN (-$0.72)

Tonight’s percentage (%) indicators:

Review the range of the 22 upside from +0.27% (FIXX) to +9.86% (BLCM) while the 18 downside ranged from -0.41% (OSIR) to -9.88% (HSGX) with a 5 flat close (MESO, CLBS, BSTG, ATHX and AGTC).

Volume stat:

7 out of 22 upside had higher (than the 3 month average) volume
8 out of 18 downside experienced greater volume (than the 3 month average).

November sessions:

Friday closed POSITIVE with 18 decliners, 22 advancers and 5 flats;

Thursday closed NEGATIVE with 24 decliners, 20 advancers and 1 flat;

Wednesday closed POSITIVE with 10 decliners, 34 advancers and 1 flat;

Tuesday closed NEGATIVE with 37 decliners, 7 advancers and 1 flat;

Monday closed POSITIVE with 18 decliners, 25 advancers and 2 flat;

Friday’s closed POSITIVE with 17 decliners, 27 advancers and 1 flat;

Thursday was a holiday

Wednesday closed POSITIVE with 8 decliners, 37 advancers and 0 flat;

Tuesday closed NEGATIVE with 29 decliners, 14 advancers and 2 flat;

Monday closed NEGATIVE with 37 decliners, 7 advancers and 1 flat;

Friday closed POSITIVE with 14 decliners, 28 advancers and 3 flat;

Thursday closed POSITIVE with 12 decliners, 33 advancers and 0 flat;

Wednesday closed NEGATIVE with 36 decliners, 7 advancers and 2 flats;

Tuesday closed NEUTRAL with 21 decliners, 21 advancers and 3 flats;

Monday closed NEGATIVE with 40 decliners, 4 advancers and 1 flat;

Friday closed NEGATIVE with 39 decliners, 6 advancers and 0 flat;

Thursday closed NEGATIVE with 26 decliners, 19 advancers and 1 flat;

Wednesday closed POSITIVE with 12 decliners, 32 advancers and 1 flat;

Tuesday closed NEGATIVE with 22 decliners, 21 advancers and 2 flats;

Monday closed NEGATIVE with 35 decliners, 7 advancers and 3 flats;

Friday closed POSITIVE with 20 decliners, 22 advancers and 3 flats;

Thursday (11/1) closed POSITIVE with 3 decliners, 42 advancers and 0 flat

In 23 sessions in October – there were 17 negative closes and 6 positive closes
In 19 sessions in September – there were 10 negative closes and 9 positive close;
In 21 August sessions – 6 had negative and 15 had positive closes

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

6 hours 5 min ago
RegMed Investors’ (RMi) pre-open: head and knee down

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.